Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03735875
Recruitment Status : Recruiting
First Posted : November 8, 2018
Last Update Posted : July 23, 2019
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:
This phase Ib/II trial studies the side effects and best dose of venetoclax in combination with quizartinib and how well they work in treating patients with acute myeloid leukemia that has come back or does not respond to treatment, and who are FLT3-mutation positive. Venetoclax and quizartinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia With FLT3/ITD Mutation FLT3 Gene Mutation FLT3 Internal Tandem Duplication Recurrent Acute Myeloid Leukemia Refractory Acute Leukemia Drug: Quizartinib Drug: Venetoclax Phase 1 Phase 2

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 32 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib/II Study of Venetoclax in Combination With Quizartinib in FLT3-Mutated Acute Myelogenous Leukemia (AML)
Actual Study Start Date : January 25, 2019
Estimated Primary Completion Date : December 31, 2019
Estimated Study Completion Date : December 31, 2019


Arm Intervention/treatment
Experimental: Treatment (venetoclax, quizartinib)
Patients receive quizartinib PO QD on days 1-28 and venetoclax PO QD beginning on day 8 of cycle 1. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment beyond 24 cycles at the discretion of the treating physician.
Drug: Quizartinib
Given PO
Other Names:
  • AC-220
  • AC010220
  • AC220

Drug: Venetoclax
Given PO
Other Names:
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601
  • Venclexta
  • Venclyxto




Primary Outcome Measures :
  1. Maximum tolerated dose (MTD) as determined by dose limiting toxicity (Phase Ib) [ Time Frame: Up to 28 days ]
  2. Recommended phase II dose as determined by MTD (Phase Ib) [ Time Frame: Up to 28 days ]
  3. Composite complete remission rate (CRc) rate including CR + complete remission with incomplete platelet recovery (CRp) + complete remission with incomplete count recovery (CRi) (Phase II) [ Time Frame: Within 3 months of treatment initiation ]

Secondary Outcome Measures :
  1. Composite CRc rate including CR + CRp + CRi (Phase Ib) [ Time Frame: Within 3 months of treatment initiation ]
  2. Overall response rate (ORR) including CRc + partial remission (PR) (Phase Ib) [ Time Frame: Within 3 months of treatment initiation ]
  3. Duration of response (DOR) (Phase Ib) [ Time Frame: Up to 5 years ]
  4. Progression free survival (PFS) (Phase Ib) [ Time Frame: Up to 5 years ]
  5. Event-free survival (EFS) (Phase Ib) [ Time Frame: Up to 5 years ]
  6. Overall survival (OS) (Phase Ib) [ Time Frame: Up to 5 years ]
  7. Number of patients bridged to hematopoietic stem cell transplant (HSCT) (Phase Ib) [ Time Frame: Up to 5 years ]
  8. Median duration to HSCT (Phase Ib) [ Time Frame: From the start of study treatment up to 5 years ]
  9. Characterization of pharmacokinetic profiles (Phase Ib) [ Time Frame: Up to 5 years ]
  10. ORR (Phase II) [ Time Frame: Within 3 months of treatment initiation ]
  11. DOR (Phase II) [ Time Frame: Up to 5 years ]
  12. PFS (Phase II) [ Time Frame: Up to 5 years ]
  13. EFS (Phase II) [ Time Frame: Up to 5 years ]
  14. OS (Phase II) [ Time Frame: up to 5 years ]
  15. Number of patients bridged to hematopoietic stem cell transplant (HSCT) (Phase II) [ Time Frame: Up to 5 years ]
  16. Median duration to HSCT (Phase II) [ Time Frame: From the start of study treatment up to 5 years ]
  17. Incidence of adverse events (Phase II) [ Time Frame: Up to 5 years ]

Other Outcome Measures:
  1. Assessment of gene sequencing and clinical response to combination treatment [ Time Frame: Up to 5 years ]
  2. Changes of FLT3-internal tandem duplication (ITD) allelic burden [ Time Frame: Up to 5 years ]
  3. Pharmacodynamic parameters of biomarker inhibition [ Time Frame: Up to 5 years ]
  4. Immune modulation analysis [ Time Frame: Up to 5 years ]
  5. Analysis of surplus blood and tissue including bone marrow for future exploratory research [ Time Frame: Up to 5 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • FLT3-ITD mutated patients with relapsed/refractory AML (up to four prior therapeutic regimens for AML i.e. up to salvage 4 AML), including patients who may have been previously exposed to prior FLT3-inhibitor/s other than quizartinib (stem cell transplant [SCT] or stem cell therapy for patients who previously underwent SCT/stem cell therapy in remission will not be considered a salvage regimen)
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • Potassium, magnesium, and calcium (normalized for albumin) levels should be within institutional normal limits
  • Serum direct bilirubin =< 1.5 x upper limit normal (ULN) (or =< 3.0 x ULN if deemed to be elevated due to leukemia)
  • Alanine aminotransferase and/or aspartate aminotransferase (aspartate transaminase) =< 2.5 x ULN (or =< 5.0 x ULN if deemed elevated due to leukemia)
  • Subjects with documented Gilbert's Syndrome may have a total bilirubin > 1.5 x ULN
  • Potassium levels should be within institutional normal limits
  • Magnesium levels should be within institutional normal limits
  • Calcium (normalized for albumin) levels should be within institutional normal limits
  • Adequate renal function as demonstrated by a serum creatinine =< 1.8
  • Patients must provide written informed consent
  • With the exception of patients with rapidly proliferative disease, the interval from prior treatment to time of initiation of venetoclax and quizartinib administration will be at least 14 days or at least 5 half-lives (whichever is shorter) for cytotoxic/noncytotoxic agents. The half-life for the therapy in question will be based on published pharmacokinetic literature (abstracts, manuscripts, investigator brochure's, or drug-administration manuals) and will be documented in the protocol eligibility document. The use of chemotherapeutic or anti-leukemic agents is not permitted during the study with the following exceptions:

    • Intrathecal (IT) therapy for patients with controlled central nervous system (CNS) leukemia at the discretion of the principal investigator (PI). Controlled CNS leukemia is defined by the absence of active clinical signs of CNS disease and no evidence of CNS leukemia on the most recent 2 simultaneous cerebrospinal fluid (CSF) evaluations
    • Use of one dose of cytarabine (up to 2 g/m^2) or hydroxyurea for patients with rapidly proliferative disease is allowed before the start of study therapy and on therapy. These medications will be recorded in the case-report form
  • Baseline ejection fraction by echocardiogram (ECHO) or multigated acquisition scan (MUGA) must be >= 50%
  • Women of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy
  • Women of childbearing potential must agree to have a negative serum or beta human chorionic gonadotropin (Beta-hCG) pregnancy test result within 7 days prior to the first dose of study drugs and must agree to use an effective contraception method during the study and for 90 days following the last dose of the study. Men who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 90 days following the last dose of study drug

Exclusion Criteria:

  • Subject has t(8;21) or inv(16) karyotype abnormalities
  • Subject has acute promyelocytic leukemia (French-American-British Class M3 AML)
  • Prior exposure to quizartinib at any time in the past
  • Serum potassium < 3.5 mEq/L despite supplementation, or > 5.5 mEq/L. Serum magnesium above or below the institutional normal limit despite adequate management. Serum calcium (corrected for albumin levels) above or below institutional normal limit despite adequate management
  • Patients with known allergy or hypersensitivity to quizartinib, venetoclax or any of their components
  • Subject with a known history of being human immunodeficiency virus (HIV) positive (due to potential drug-drug interactions between antiretroviral medications and venetoclax, as well as anticipated venetoclax mechanism-based lymphopenia that may potentially increase the risk of opportunistic infections)

    • Note: HIV testing is not required
  • Subject has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or star fruit within 3 days prior to the initiation of study treatment
  • Subject has a significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, or any other medical condition that in the opinion of the investigator and/or the PI would adversely affect his/her participating in this study. Patients who have had any major surgical procedure within 14 days of day 1
  • Subject has a malabsorption syndrome or other condition that precludes enteral route of administration
  • Subject exhibits evidence of other clinically significant uncontrolled condition(s) including, but not limited to: a. Uncontrolled systemic infection requiring intravenous (IV) therapy (viral, bacterial or fungal). Infections controlled on concurrent anti-microbial agents are acceptable, and anti-microbial prophylaxis per institutional guidelines is acceptable. Patients with neutropenic fever considered infection related should be afebrile for at least 72 hours prior to first dose
  • Subject has a history of other malignancies within 1 year prior to study entry, with the exception of:

    • Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast
    • Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin
    • Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent
    • Patients on active antineoplastic or radiation therapy for a concurrent malignancy at the time of screening. Maintenance therapy, hormonal therapy, or steroid therapy for well-controlled malignancy is allowed
  • Patients with a known positive hepatitis B or C infection by serology, with the exception of those with an undetectable viral load within 3 months (hepatitis B or C testing is not required prior to study entry). Subjects with serologic evidence of prior vaccination to hepatitis B virus (HBV) (i.e., hepatitis B surface antigen negative [HBs Ag-], and hepatitis B surface antibody positive [anti-HBs+]) may participate
  • Female subjects who are pregnant or breastfeeding
  • Impaired cardiac function including any of the following:

    • Screening electrocardiogram (ECG) with a corrected QT (QTc) > 450 msec. The QTc interval will be calculated by Fridericia's correction factor (QTcF) at screening and on day 1 prior to the first dose of quizartinib. The QTcF will be derived from the average QTcF in triplicate. If QTcF > 450 msec on Day 1, quizartinib will not be given.
    • Patients with congenital long QT syndrome
    • History or presence of sustained ventricular tachycardia requiring medical intervention within 3 months prior to starting study drug
    • Any history of clinically significant ventricular fibrillation or torsades de pointes
    • Known history of second or third degree heart block (may be eligible if the patient currently has a pacemaker) within 3 months prior to starting study drug
    • Sustained heart rate of < 50/minute on screening or day 1 ECG
    • Right bundle branch block + left anterior hemiblock (i.e. bifascicular block)
    • Isolated right bundle branch block (RBBB) will not be an exclusion criterion
    • Complete left bundle branch block
    • Patients with myocardial infarction or unstable angina within 6 months prior to starting study drug
    • Congestive heart failure (CHF) New York (NY) Heart Association class III or IV within 3 months prior to starting study drug
    • Atrial fibrillation documented within 2 weeks prior to first dose of study drug
    • Patients who are actively taking CYP3A inducers. CYP3A4 inducers should be stopped at least 3 days prior to the first dose of quizartinib and are prohibited at any time on study. Moderate and strong CYP3A4 inhibitors should be stopped at least 3 days prior to the first dose of quizartinib and are prohibited during cycle 1. Moderate (but not strong) CYP3A4 inhibitors may be used with the below dose reductions of venetoclax after cycle 1. Patients may receive weak CYP3A4 inhibitors at any time on study. The venetoclax and quizartinib doses do not need to be adjusted for weak CYP3A4 inhibitors
    • Patients who require treatment with concomitant drugs that prolong QT/QTc interval. QT/QTc prolonging drugs should be stopped at least 3 days prior to the first dose of quizartinib and are prohibited at any time on study
    • Known family history of congenital long QT syndrome

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03735875


Contacts
Layout table for location contacts
Contact: Naval Daver 713-794-4392 ndaver@mdanderson.org

Locations
Layout table for location information
United States, Texas
M D Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Naval G. Daver    713-794-4392      
Principal Investigator: Naval G. Daver         
Sponsors and Collaborators
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Naval G Daver M.D. Anderson Cancer Center

Additional Information:
Layout table for additonal information
Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT03735875     History of Changes
Other Study ID Numbers: 2018-0608
NCI-2018-02396 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
2018-0608 ( Other Identifier: M D Anderson Cancer Center )
P30CA016672 ( U.S. NIH Grant/Contract )
First Posted: November 8, 2018    Key Record Dates
Last Update Posted: July 23, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Neoplasms
Venetoclax
Antineoplastic Agents